Evidence map›Paper›PMID 35408492›Full record

ArticleMolecules (Basel, Switzerland)2022

Effects of Artonin E on Cell Growth Inhibition and Apoptosis Induction in Colon Cancer LoVo and HCT116 Cells.

Kanyaluck Yangnok, Sukanda Innajak, Ratchawin Sawasjirakij, Wilawan Mahabusarakam, Ramida Watanapokasin

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Kanyaluck YangnokDepartment of Biochemistry, Faculty of Medicine, Srinakharinwirot University, Bangkok 10110, Thailand.
Sukanda InnajakDepartment of Biochemistry, Faculty of Medicine, Srinakharinwirot University, Bangkok 10110, Thailand.ORCID 0000-0002-3340-9844
Ratchawin SawasjirakijFaculty of Medicine, Medical University of Lublin, Aleje Racławickie 1, 20-059 Lublin, Poland.
Wilawan MahabusarakamDepartment of Chemistry, Faculty of Science, Prince of Songkla University, Hat Yai 90112, Thailand.
Ramida WatanapokasinDepartment of Biochemistry, Faculty of Medicine, Srinakharinwirot University, Bangkok 10110, Thailand.ORCID 0000-0001-8333-3238
Srinakharinwirot University · THMedical University of Lublin · PLPrince of Songkla University · TH

Funding

Research Division, Faculty of Medicine, Srinakharinwirot University, Thailand. 391/2563
6 · The paper itself

Abstract

Today, colon cancer is the leading cause of cancer death. In Thailand, colon cancer is the third most common cancer in men and the second in women. Currently, the treatments for colon cancer include surgery, chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted drug therapy, and stem cell therapy. However, some treatments have side effects for cancer patients, causing unwanted symptoms. In addition, targeted therapy comes with a high cost for patients. Therefore, bioactive compounds might be a good choice for colon cancer treatment. In this study, we investigated the effect of artonin E on apoptosis induction in colon cancer LoVo and HCT116 cells. The concentration ranges of artonin E at 3, 5, 10, and 30 µg/mL in LoVo cells and 1, 1.5, 2, and 3 µg/mL in HCT116 cells were examined. The results implied that artonin E decreased cell viability and increased apoptotic cells in a dose-dependent manner. In addition, artonin E stimulated mitochondrial membrane potential (Δ

Indexed as

Colonic NeoplasmsApoptosisCell Line, TumorFemaleFlavonoidsHCT116 CellsHumansartonin EFlavonoidsapoptosisartonin Ecolon cancerMAPK

Identifiers

PMID35408492
PMCPMC9000836
OpenAlexW4220975234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.